Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Black Diamond Therapeutics, Inc. (BDTX)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 0.0 | 0.0 | 95.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 95.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | 100.0% | | | | | |
| Selling, general and administrative [+] | 6.9 | 6.8 | 7.2 | 6.3 | 7.0 | 7.9 | 6.4 | 7.7 |
| General and administrative | 6.9 | 6.8 | 7.2 | 6.3 | 7.0 | 7.9 | 6.4 | 7.7 |
| Research and development | 13.2 | 14.8 | 14.6 | 15.8 | 16.2 | 17.8 | 19.7 | 27.6 |
| Equity in earnings | | | -2.3 | | | | | |
| Other operating expenses | | | 92.8 | | | | | |
| EBITDA [+] | -19.9 | -21.4 | -21.7 | -22.0 | -23.0 | -25.6 | -26.0 | -35.3 |
| EBITDA growth | -13.6% | -16.1% | -16.2% | -37.7% | -33.6% | -16.7% | 12.0% | 91.3% |
| EBITDA margin | | | -22.9% | | | | | |
| Depreciation and amortization | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| EBIT [+] | -20.0 | -21.6 | -21.9 | -22.1 | -23.2 | -25.7 | -26.1 | -35.4 |
| EBIT growth | -13.6% | -16.0% | -16.1% | -37.4% | -33.2% | -16.4% | 12.5% | 91.4% |
| EBIT margin | | | -23.0% | | | | | |
| Non-recurring items | | | 2.2 | | | | | |
| Interest income | 0.5 | 0.6 | 0.7 | 0.6 | 0.4 | 0.4 | 0.6 | 0.8 |
| Interest income | 0.5 | 0.6 | 0.7 | 0.6 | 0.4 | 0.4 | 0.6 | 0.8 |
| Other income (expense), net [+] | 0.3 | 0.1 | 2.3 | -0.1 | -0.1 | -0.2 | -0.4 | -0.5 |
| Other | 0.3 | 0.1 | 0.1 | -0.1 | -0.1 | -0.2 | -0.4 | -0.5 |
| Pre-tax income | -19.2 | -20.9 | -21.1 | -21.7 | -22.9 | -25.5 | -25.9 | -35.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -19.2 | -20.9 | -21.1 | -21.7 | -22.9 | -25.5 | -25.9 | -35.1 |
| Net margin | | | -22.2% | | | | | |
| |
| Basic EPS [+] | ($0.52) | ($0.57) | ($0.58) | ($0.60) | ($0.63) | ($0.70) | ($0.71) | ($0.97) |
| Growth | -17.0% | -18.6% | -18.8% | -38.5% | -33.5% | -16.2% | 4.0% | 94.3% |
| Diluted EPS [+] | ($0.52) | ($0.57) | ($0.58) | ($0.60) | ($0.63) | ($0.70) | ($0.71) | ($0.97) |
| Growth | -17.0% | -18.6% | -18.8% | -38.5% | -33.5% | -16.2% | 4.0% | 94.3% |
| |
| Shares outstanding (basic) [+] | 36.5 | 36.5 | 36.3 | 36.3 | 36.3 | 36.3 | 36.2 | 36.2 |
| Growth | 0.6% | 0.6% | 0.4% | 0.4% | 0.3% | 0.4% | 10.0% | 0.8% |
| Shares outstanding (diluted) [+] | 36.5 | 36.5 | 36.3 | 36.3 | 36.3 | 36.3 | 36.2 | 36.2 |
| Growth | 0.6% | 0.6% | 0.4% | 0.4% | 0.3% | 0.4% | 10.0% | 0.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|